ARTICLE | Company News
PharmAthene, National Institutes of Health infectious news
October 6, 2008 7:00 AM UTC
PharmAthene received a three-year, $13.2 million contract from the NIH's National Institute of Allergy and Infectious Disease (NIAID) to develop a third-generation recombinant protective antigen ( rPA...